secwatch.observer — SEC 8-K summary
======================================

Issuer:     SYNLOGIC, INC. (SYBX)
CIK:        0001527599
Form:       8-K
Filed at:   2024-11-12T23:59:59+00:00
Accession:  0000950170-24-125523
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Synlogic posts Q3 net loss of $0.1M, cash $19.4M; evaluating strategic options
------------------------------------------------------------------------------

- Net loss of $0.1M ($0.01 per share) vs $12.1M ($2.57 loss per share) in Q3 2023.
- Cash and cash equivalents of $19.4M as of Sep 30, 2024; no revenue for Q3.
- R&D expenses show $0.7M benefit due to clinical trial refund and accrual reversal.
- Restructuring charges of $0.3M related to workforce reduction from Synpheny-3 discontinuation.
- Retained Lucid Capital Markets to explore strategic alternatives including M&A or business combination.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1527599/000095017024125523/0000950170-24-125523-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1527599/000095017024125523/sybx-20241112.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-125523

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer